+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antispasmodics Drugs Market - Global Forecast 2026-2032- Product Image
Antispasmodics Drugs Market - Global Forecast 2026-2032- Product Image
New

Antispasmodics Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336390
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antispasmodics drugs market is undergoing transformation, shaped by shifting clinical priorities, advancements in drug formulations, supply chain reconfiguration, and regulatory developments. Decision-makers require actionable insights to navigate increasing complexity, manage risk, and maintain growth in this evolving landscape.

Market Snapshot: Antispasmodics Drugs Market

The Antispasmodics Drugs Market grew from USD 13.23 billion in 2025 to USD 14.56 billion in 2026. It is expected to continue growing at a CAGR of 10.66%, reaching USD 26.89 billion by 2032. This trajectory reflects expanding clinical applications, rapid formulation innovations, and commercial adaptation to global health and trade challenges.

Scope & Segmentation

  • Formulation Types: Capsules (hard shell, soft gel), coated/uncoated tablets, injectable preparations (intramuscular, intravenous, subcutaneous), syrups, and topical formats (cream, gel, patch).
  • Administration Routes: Oral (chronic care), parenteral (acute/inpatient use), and topical (local effect, systemic-sparing).
  • Mechanisms of Action: Anticholinergics, calcium channel blockers, GABA agonists, with variable safety and efficacy profiles.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy, each shaping access and reimbursement dynamics.
  • Clinical Applications: Treatment of gastrointestinal (IBS, peptic ulcer, spastic colon), gynecological (dysmenorrhea, endometriosis), and urinary conditions (cystitis, overactive bladder).
  • End-User Profiles: Clinics and hospitals, with tailored engagement strategies aligned to formulary and outpatient care requirements.
  • Geographic Regions: Americas, EMEA, and Asia-Pacific, each region characterized by distinct regulatory frameworks, payer structures, and healthcare infrastructure.

Antispasmodics Drugs Market: Key Takeaways

  • Market participants must adapt to regulatory scrutiny, with increased emphasis on safety labeling, post-market pharmacovigilance, and payer-focused evidence generation.
  • Advancements in drug delivery—such as soft gel capsules, patches, and oral liquids—accelerate the transition to patient-preferred, adherence-friendly therapies.
  • Supply chain resilience requires qualification of alternate suppliers, investment in regional fill-and-finish capabilities, and ongoing response to geopolitical risk factors.
  • Commercial models must reflect channel diversity, integrating digital pharmacy, hospital procurement strategies, and patient services tailored for outpatient and institutional settings.
  • Technological innovation, including novel mechanism discovery beyond classical anticholinergics, is advancing the portfolio for refractory symptom clusters and enabling wider label claims.
  • Operational excellence and evidence-driven value communication are essential levers for institutional access and sustainable market positioning.

Tariff Impact and Trade Dynamics

Recent shifts in U.S. tariff policy have made supply chain decision-making more complex for antispasmodic manufacturers. Heightened duties and customs friction are prompting greater supplier diversification, contract renegotiation, and investments in nearshoring or local manufacturing to buffer against transit disruptions and import cost volatility. Contractual flexibility, risk-sharing, and lockstep inventory management have become vital for production continuity and price defense. Payor and hospital procurement behaviors are further evolving in response, driving manufacturers to emphasize formulations that combine clinical value with cost-control potential. Expedited regulatory processes for essential medicines may mitigate delays, but compliance requirements and border logistics continue to shape sourcing strategy and risk exposure.

Methodology & Data Sources

The research is underpinned by a mixed-methods approach, combining structured interviews with clinicians, pharmacists, procurement professionals, and industry executives, alongside thorough literature and regulatory reviews. Data segmentation is validated through expert triangulation and cross-checked with multiple quantitative sources for accuracy and consistency.

Why This Report Matters

  • Enables senior executives to align R&D, commercial, and supply chain strategies to current market realities and anticipated trends.
  • Facilitates competitive benchmarking through clear segmentation and channel analysis across regions, clinical applications, and product types.
  • Supports proactive risk management and opportunity identification in the face of evolving tariffs, regional regulations, and channel fragmentation.

Conclusion

Leaders in the antispasmodics drugs market who prioritize innovation, evidence-based commercial models, and operational resilience will secure competitive differentiation and adapt more effectively to market change. Sustained vigilance across regulatory, supply chain, and channel fronts remains essential for long-term success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antispasmodics Drugs Market, by Formulation
8.1. Capsule
8.1.1. Hard Shell
8.1.2. Soft Gel
8.2. Injection
8.2.1. Intramuscular
8.2.2. Intravenous
8.2.3. Subcutaneous
8.3. Syrup
8.4. Tablet
8.4.1. Coated
8.4.2. Uncoated
9. Antispasmodics Drugs Market, by Route
9.1. Oral
9.2. Parenteral
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Topical
9.3.1. Cream
9.3.2. Gel
9.3.3. Patch
10. Antispasmodics Drugs Market, by Mechanism
10.1. Anticholinergics
10.2. Calcium Channel Blockers
10.3. GABA Agonists
11. Antispasmodics Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Antispasmodics Drugs Market, by Application
12.1. Gastrointestinal Disorders
12.1.1. Irritable Bowel Syndrome
12.1.2. Peptic Ulcer
12.1.3. Spastic Colon
12.2. Gynecological Disorders
12.2.1. Dysmenorrhea
12.2.2. Endometriosis
12.3. Urinary Disorders
12.3.1. Cystitis
12.3.2. Overactive Bladder
13. Antispasmodics Drugs Market, by End User
13.1. Clinics
13.2. Hospitals
14. Antispasmodics Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Antispasmodics Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Antispasmodics Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Antispasmodics Drugs Market
18. China Antispasmodics Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Almirall, S.A.
19.6. Boehringer Ingelheim International GmbH
19.7. Dr. Reddy's Laboratories Limited
19.8. Glenmark Pharmaceuticals Limited
19.9. Pfizer Inc.
19.10. Sandoz International GmbH
19.11. Sanofi S.A.
19.12. Sun Pharmaceutical Industries Ltd.
19.13. Teva Pharmaceutical Industries Ltd.
19.14. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA ANTISPASMODICS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 190. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 191. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 192. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 193. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 194. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 195. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 196. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 197. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 200. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 201. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 202. EUROPE ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 220. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 221. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 222. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 223. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 224. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 225. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 226. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 227. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 229. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 230. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 231. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 232. AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 251. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 252. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 253. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 254. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 255. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 256. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 257. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 258. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 259. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 260. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 261. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 262. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 263. ASEAN ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 266. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 267. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 268. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 269. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 270. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 271. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 272. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 273. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 274. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 275. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 276. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 277. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 278. GCC ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 295. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 296. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 297. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 298. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 299. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 300. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 301. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 302. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 303. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 305. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 306. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 307. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 308. BRICS ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 309. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 310. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 311. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 312. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 313. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 314. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 315. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 316. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 317. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 318. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 319. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 320. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 321. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 322. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2032 (USD MILLION)
TABLE 323. G7 ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 325. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 326. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 327. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 328. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 329. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
TABLE 330. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 331. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 332. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
TABLE 333. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 334. NATO ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 335. NATO ANTISPASMO

Companies Mentioned

The key companies profiled in this Antispasmodics Drugs market report include:
  • Almirall, S.A.
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 14.56 Billion
Forecasted Market Value ( USD ) by 2032 $ 26.89 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antispasmodics Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antispasmodics Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antispasmodics Drugs Market Report 2025 - Product Image

Antispasmodics Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Hyoscine N Butyl Bromide Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Hyoscine N Butyl Bromide Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cerebral Palsy Treatment Market - Global Forecast 2026-2032 - Product Image

Cerebral Palsy Treatment Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Quadriplegia Treatment Market Report 2025 - Product Image

Quadriplegia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Muscle Spasm Drug Market

The Muscle Spasm Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat muscle spasms, which are involuntary contractions of the muscles. These drugs are used to reduce pain and discomfort associated with muscle spasms, as well as to improve mobility. Commonly used muscle spasm drugs include muscle relaxants, antispasmodics, and anticonvulsants. These drugs are typically prescribed by a physician and are available in both oral and injectable forms. The Muscle Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, GlaxoSmithKline, Merck, and Sanofi. Other companies in the market include AbbVie, AstraZeneca, Teva Pharmaceuticals, and Mylan. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.